Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561781 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01561781 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 14 participants.
The verdict
NCT01561781, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a study in healthy volunteers to assess the pharmacokinetics (PK) of Digoxin administered alone and in combination with Vandetanib.
Interventions
- DRUG Digoxin
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561781
The ClinicalTrials.gov registry entry for NCT01561781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Digoxin is the first listed.
NCT01561781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01561781 about?
NCT01561781 is a clinical study titled "Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib". This is a study in healthy volunteers to assess the pharmacokinetics (PK) of Digoxin administered alone and in combination with Vandetanib.
What is the current status of trial NCT01561781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01561781?
The interventions under investigation include: Digoxin (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT01561781?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.